Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
July 21, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
June 09, 2022 07:35 ET
|
Olema Oncology
Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansionCombinability with CDK4/6i palbociclib demonstrated across initial dose...
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
June 09, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, June 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Present at Jefferies Healthcare Conference
May 24, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, May 24, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:30 ET
|
Olema Oncology
Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose expected in Q2 2022Phase 1b combination study with palbociclib ongoing;...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...